Ocular Therapeutix, INC 8-K filings

Ocular Therapeutix announced a clear FDA-aligned path for its AXPAXLI NDA submission in Q4 2026, supported by positive Phase 3 data and a strong cash position extending into 2028.

Ocular Therapeutix confirmed the appointment of Jason Robins as CFO and secured shareholder approval for a 10 million share increase to its 2021 Stock Incentive Plan.

Ocular Therapeutix reported Q1 2026 financial results, highlighting positive Phase 3 SOL-1 trial data for AXPAXLI in wet AMD and providing updates on ongoing clinical programs.

Ocular Therapeutix, Inc. announced it will present detailed Phase 3 clinical trial results for AXPAXLI in wet age-related macular degeneration at the 49th Macula Society Annual Meeting.

Ocular Therapeutix announced its fourth quarter and full year 2025 financial results, highlighted by upcoming Phase 3 trial data for AXPAXLI in wet AMD and a strong cash position.

Ocular Therapeutix announces its Chief Financial Officer and Chief Operating Officer, Donald Notman, is taking a temporary medical leave, with Jason Robins appointed as interim CFO.

Ocular Therapeutix, Inc. announced a quiet period starting December 20, 2025, as it prepares for database lock for its AXPAXLI Phase 3 clinical trial, with data expected in Q1 2026.

Ocular Therapeutix plans to submit a New Drug Application for AXPAXLI based on year 1 SOL-1 Phase 3 data, following updated FDA guidance.

Ocular Therapeutix reported its third-quarter 2025 financial results, highlighted by significant progress in its AXPAXLI clinical trials and a strengthened cash position following a recent equity offering.

Ocular Therapeutix, Inc. announced the pricing of an underwritten public offering of 37.9 million common shares, raising approximately $445.9 million in net proceeds to extend its cash runway into 2028.

Ocular Therapeutix, Inc. provided comprehensive updates on its AXPAXLI development programs for wet AMD and non-proliferative diabetic retinopathy, alongside new intellectual property protection.

Ocular Therapeutix reported a wider net loss in Q2 2025 due to increased R&D for its AXPAXLI wet AMD trials, while securing a strong cash position into 2028.

Ocular Therapeutix, Inc. announced stockholder approval of amendments to its stock incentive and employee stock purchase plans, officer exculpation, director elections, and the completion of enrollment in its SOL-R Phase 3 clinical trial for AXPAXLI.

Ocular Therapeutix announced its Q1 2025 financial results, highlighting progress in AXPAXLI clinical trials for wet AMD and NPDR, and a strong cash position expected to last into 2028.

Ocular Therapeutix reports key updates to its AXPAXLI registrational program for wet AMD, including FDA agreement on re-dosing and a reduced SOL-R trial size, alongside Q4 and full year 2024 financial results.

Ocular Therapeutix approves a new compensation package for CEO Pravin Dugel, including a base salary increase, bonuses, and long-term equity awards tied to stock price performance.

Ocular Therapeutix reports positive progress in its Phase 3 trials for AXPAXLI in wet AMD, with SOL-1 expected to be fully randomized by year-end 2024 and a strong cash balance to fund operations into 2028.

Ocular Therapeutix has amended its 2019 Inducement Stock Incentive Plan to increase the number of shares available for issuance.

Ocular Therapeutix has appointed Donald Notman, the current Chief Financial Officer, to the additional role of Chief Operating Officer, effective August 29, 2024.

Ocular Therapeutix reports positive progress in its wet AMD clinical trials, with the FDA accepting the SOL-R study as registrational, and a strong cash balance of $459.7 million expected to fund operations into 2028.

Ocular Therapeutix's stockholders approved an increase in authorized shares and an expansion of the company's stock incentive plan at the 2024 Annual Meeting.

Ocular Therapeutix is reducing its workforce by 13% to prioritize the clinical development of its AXPAXLI treatment for wet age-related macular degeneration.

Ocular Therapeutix announced its first quarter 2024 financial results, highlighted by a $325 million private financing and progress in its Phase 3 wet AMD trial.

Ocular Therapeutix has appointed Pravin U. Dugel, M.D., as its new President and CEO, succeeding Antony C. Mattessich, and Nadia Waheed, M.D., as Chief Medical Officer, while also increasing the shares available under its 2019 Inducement Stock Incentive Plan.

Ocular Therapeutix has amended its employment agreement with Medical Director, Peter Kaiser, M.D., removing the 50% service requirement.

Ocular Therapeutix announced its fourth quarter and full year 2023 financial results, highlighted by increased revenue and significant progress in its clinical programs, along with a strengthened leadership team and a substantial capital raise.

Biopharmaceutical company Ocular Therapeutix, Inc. has announced a $325 million private placement to accelerate the clinical development of its innovative therapies for diseases and conditions of the eye.

Ocular Therapeutix has secured FDA agreement on a modified Special Protocol Assessment for its Phase 3 SOL trial of AXPAXLI, allowing for broader patient inclusion and an optimized implant design.